FRAX and the assessment of the risk of developing a fragility fracture

Journal of Bone and Joint Surgery - Series B

Volumn 94 B, Issue 10, 2012, Pages 1313-1320

  Middleton, R G ^a,e   Shabani, F ^b,e   Uzoigwe, C E ^c,e   Shoaib, A ^d,e   Moqsith, M ^e   Venkatesan, M ^e  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^b ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

^d KETTERING GENERAL HOSPITAL   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY; CLINICAL ASSESSMENT TOOL; DENSITOMETRY; FRACTURE RISK ASSESSMENT TOOL; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84867316875     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.94B10.28889     Document Type: Review

References (67)

1. Kanis JA. World Health Organization Collaborating Centre for Metabolic Bone Diseases. Assessment of osteoporosis at the primary health-care level. http://www.shef.ac.uk/FRAX/pdfs/WHO-Technical-Report.pdf (date last accessed 8 June 2012.
2. Goklany IM. The improving state of the world: why we're living longer, healthier, more comfortable lives on a cleaner planet. Washington: Cato Institute, 2007.
3. Wu TY, Jen MH, Bottle A, et al. Admission rates and in-hospital mortality for hip fractures in England 1998 to 2009: time trends study. J Public Health (Oxf) 2011;33:284-291.
4. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573-1579.
5. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009;301:513-521.
6. Burge RT, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporotic fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475. (Pubitemid 46797130)
7. No authors listed. Bone health and osteoporosis: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Office of the Surgeon General, 2004.
8. Ström O, Borgström F, Kanis JA, et al. Osteoporosis: Burden, health care provision and opportunities in the European Union. Arch Osteoporos 2011;6:9080.
9. Wang Y, Tao Y, Hyman ME, Li J, Chen Y. Osteoporosis in China. Osteoporos Int 2009;20:1651-1662.
10. Nguyen TV, Center JR, Eisman JA. Osteoporosis: underrated, underdiagnosed and undertreated. Med J Aust 2004;180(Suppl):S18-S22. (Pubitemid 38313000)
11. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int 2005;16:134-141. (Pubitemid 40193199)
12. No authors listed. World Health Organization. The world health report 1997: conquering suffering, enriching humanity. http://www.who.int/whr/1997/en/ index.html (date last accessed 8 June 2012).
13. No authors listed. World Health Organization Geneva. Guidelines for preclinical evaluation and clinical trials in osteoporosis, 1998:59. http://whqlibdoc.who.int/publications/1998/9241545224-eng.pdf (date last accessed 8 June 2012).
14. Kanis JA, Glüer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos Int 2000;11:192-202.
15. No authors listed. British Geriatrics Society. The care of patients with fragility fracture ("blue book"), 2007. http://www.bgs.org.uk/index. php?option=com-content&view=article&id=338: bluebookfragilityfracture&catid=47:fallsandbones&Itemid=147 (date last accessed 8 June 2012).
16. Delmas PD. Do we need to change the WHO definition of osteoporosis? Osteoporos Int 2000;11:189-191. (Pubitemid 30216169)
17. No authors listed. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended), 2011 (TA160). http://www.nice.org.uk/guidance/TA160/Guidance/pdf (date last accessed 8 June 2012).
18. Sanders KM, Nicholson GC, Watts JJ, et al. Half the burden of fragility fractures in the community occur in women without osteoporosis: when is fracture prevention cost-effective? Bone 2006;38:694-700.
19. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-1112. (Pubitemid 38668990)
20. No authors listed. World Health Organization Geneva. Prevention and management of osteoporosis, 2003. http://whqlibdoc.who.int/trs/WHO-TRS-921.pdf (date last accessed 8 June 2012).
21. Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg [Am] 2010;92-A:743-753.
22. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 1990;322:1635-1641. (Pubitemid 20171587)
23. No authors listed. National Cholesterol Education Program. Risk assessment tool for estimating your 10-year risk of having a heart attack. http://hp2010.nhlbihin.net/atpiii/calculator.asp (date last accessed 8 June 2012).
24. No authors listed. World Health Organization. WHO CVD-Risk Management Package. http://www.who.int/cardiovascular-diseases/priorities/management/ package/en/ (date last accessed 8 June 2012).
25. No authors listed. National Institute for Health and Clinical Excellence. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease, 2008 (CG67). www.nice.org.uk/guidance/CG67 (date last accessed 8 June 2012).
26. No authors listed. American Heart Association. Heart attack risk assessment. http://www.heart.org/HEARTORG/Conditions/HeartAttack/ HeartAttackToolsResources/Heart-Attack-Risk-Assessment-UCM-303944-Article.jsp (date last accessed 8 June 2012).
27. Dell RM, Greene D, Anderson D, Williams K. Osteoporosis disease management: what every orthopaedic surgeon should know. J Bone Joint Surg [Am] 2009;91-A(Suppl 6):79-86.
28. No authors listed. World Health Organization Collaborating Centre for Metabolic Bone Diseases. WHO fracture risk assessment tool. http://www.shef.ac. uk/FRAX/(date last accessed 8 June 2012).
29. Dimai HP, Svedbom A, Fahrleitner-Pammer A, et al. Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 2011;22:685-692.
30. Chevalley T, Guilley E, Herrmann FR, et al. Incidence of hip fracture over a 10-year period (1991-2000): reversal of a secular trend. Bone 2007;40:1284-1289. (Pubitemid 46550978)
31. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397.
32. No authors listed. National Osteoporosis Foundation. NOF Clinician's Guide to Prevention and Treatment of Osteoporosis, 2010. http://www.nof.org/ professionals/clinical-guidelines (date last accessed 8 June 2012).
33. No authors listed. International Osteoporosis Foundation. http://www.iofbonehealth. org/ (date last accessed 8 June 2012).
34. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2008;19:399-428.
35. Tosi LL, Dell RM. AAOS. Challenging orthopaedics to reduce osteoporotic hip fractures, 2012. http://www.aaos.org/news/aaosnow/may09/research5.asp (date last accessed 8 June 2012).
36. No authors listed. National Clinical Guideline Centre. Osteoporosis: fragility fracture risk, 2012. http://www.nice.org.uk/nicemedia/live/13281/ 58077/58077.pdf (date last accessed 8 June 2012).
37. Siris E, Delmas PD. Assessment of 10-year absolute fracture risk: a new paradigm with worldwide application. Osteoporos Int 2008;19:383-384.
38. Adami S, Bianchi G, Brandi ML, et al. Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. Clin Exp Rheumatol 2010;28:561-570.
39. Azagra R, Roca G, Encabo G, et al. Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX tool in Spain. BMC Musculoskelet Disord 2011;12:30.
40. Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res 2010;25:2350-2358.
41. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX® : assessment and intervention thresholds for the UK. Osteoporos Int 2008;19:1395-1408.
42. No authors listed. WHO Fracture Risk Assessment Tool. FAQ. http://www.shef.ac.uk/FRAX/faq.jsp (date last accessed 8 June 2012).
43. No authors listed. International Osteoporosis Foundation. FRAX information and resources. http://www.iofbonehealth.org/bonehealth/frax- information-and-resources (date last accessed 8 June 2012).
44. No authors listed. National Institute for Health and Clinical Excellence. Osteoporosis - secondary prevention including strontium ranelate: guidance, 2011 (TA161). http://www.nice.org.uk/guidance/TA161/Guidance/pdf (date last accessed 8 June 2012).
45. No authors listed. FRAX Release Notes. http://www.shef.ac.uk/FRAX/pdfs/ FRAX-Release-Notes.pdf (date last accessed 17 August 2012).
46. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;1:CD001155.
47. Man SF, Sin DD. Thinning bone and inhaled corticosteroid in COPD: what to do until there is definitive proof? Chest 2009;136:1448-1449.
48. Bridges MJ, Ruddick S. Are metatarsal fractures indicative of osteoporosis in postmenopausal women? Foot Ankle Spec 2011;4:271-273.
49. Kanis JA, Johnell O, Johansson H, et al. Prior clinical vertebral fractures are a particularly strong predictor of hip fracture: a meta-analysis. Osteoporosis Int 2006:17(Suppl 3):365.
50. Henry MJ, Pasco JA, Sanders KM, Nicholson GC, Kotowicz MA. Fracture Risk (FRISK) Score: Geelong Osteoporosis Study. Radiology 2006;241:190-196. (Pubitemid 44433350)
51. Lekamwasam S. Application of FRAX model to Sri Lankan postmenopausal women. J Clin Densitom 2010;13:51-55.
52. Henry BR, Houston S, Mooney GH. Institutional racism in Australian healthcare: a plea for decency. Med J Aust 2004;180:517-520. (Pubitemid 38684621)
53. Leslie WD, Lix LM, Johansson H, et al. A comparative study of using non-hip bone density inputs with FRAX®. Osteoporos Int 2012;23:853-860.
54. Unnanuntana A, Rebolledo BJ, Khair MM, DiCarlo EF, Lane JM. Diseases affecting bone quality: beyond osteoporosis. Clin Orthop Relat Res 2011;469:2194-2206.
55. No authors listed. Department of Health. Prevention package for older people resources. http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH-103146 (date last accessed 8 June 2012).
56. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008;19:437-447.
57. No authors listed. BAILII. England and Wales Court of Appeal (Civil Division) Decisions, 2010. http://www.bailii.org/ew/cases/EWCA/Civ/2010/346.html (date last accessed 8 June 2012).
58. No authors listed. ClinRisk Ltd. Welcome to the QFracture® -2012 risk calculator, 2012. http://www.qfracture.org/ (date last accessed 8 June 2012).
59. Collins GS, Mallet S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 2011;342:3651.
60. Cummins NM, Poku EK, Towler MR, O'Driscoll OM, Ralston SH. Clinical risk factors for osteoporosis in Ireland and the UK: a comparison of FRAX and QFractures. Calcif Tissue Int 2011;89:172-177.
61. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19:1431-1444.
62. Koh LK, Sedrine WB, Torralba TP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705. (Pubitemid 32889171)
63. Sedrine WB, Chevallier T, Zegels B, et al. Development and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry. Gynecol Endocrinol 2002;16:245-250. (Pubitemid 34848386)
64. Hundrup YA, Jacobsen RK, Andreasen AH, et al. Validation of a 5-year risk score of hip fracture in postmenopausal women: the Danish Nurse Cohort Study. Osteoporos Int 2010;21:2135-2142.
65. Henry MJ, Pasco JA, Merriman EN, et al. Fracture risk score and absolute risk of fracture. Radiology 2011;259:495-501.
66. Bolland MJ, Siu AT, Mason BH, et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res 2011;26:420-427.
67. Coleman MT, Newton KS. Supporting self-management in patients with chronic illness. Am Fam Physician 2005;72:1503-1510. (Pubitemid 43093402)